White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Patients HCP
This site is for US residents only.
Starting SCEMBLIX. In newly diagnosed Ph+ CML in chronic phase

In a head-to-head clinical study of adults with newly diagnosed Ph+ CML-CP

More people achieved MMR with SCEMBLIX than with commonly used TKIs* at nearly 1 year (48 weeks)

Major molecular response (MMR) is an important milestone in the treatment of Ph+ CML in chronic phase. SCEMBLIX is the only medication that went head-to-head against all the most commonly used TKIs* for newly diagnosed patients. SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel.® (dasatinib), and Bosulif ® (bosutinib).

MMR was achieved in: 68% (136 of 201) Nearly 7 out of 10 patients on SCEMBLIX vs 49% (100 of 204) Nearly 5 out of 10 patients on the most commonly used TKIs †
MMR was achieved in: 69% (70 of 101) of patients on SCEMBLIX vs 40% (41 of 102) of patient on GLEEVEC

In this clinical study, the most common side effect reported (≥ 20%) with SCEMBLIX was pain in the muscles, bones, or joints.

SCEMBLIX worked fast

The time when half of the patients in each study arm achieved MMR

In this clinical study, the most common side effect reported (≥ 20%) with SCEMBLIX was pain in the muscles, bones, or joints. Everyone responds differently to treatment. That's why it's important to discuss the potential side effects of each treatment you and your doctor are considering.

*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel® (dasatinib), and Bosulif ® (bosutinib). 
Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.

 

Milestone icon
What is MMR?

MMR is an important milestone in the treatment of Ph+ CML in the chronic phase.

Ask your doctor to consider SCEMBLIX for your first treatment.

Learn more

In a head-to-head clinical study of adults with newly diagnosed Ph+ CML-CP

More people were able to stay on SCEMBLIX for 48 weeks:

Patients who had to stop treatment specifically due to side effects at nearly 1 year (48 weeks): SCEMBLIX 4.5% (9 of 200 patients) vs other TKIs 10.4% (21 of 201 patients)

*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). 
Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.

Common side effects of SCEMBLIX

The most common side effects of SCEMBLIX include:

  • muscle, bone, or joint pain

  • rash

  • tiredness

  • nose, throat, or sinus (upper respiratory tract) infections

  • headache

  • stomach-area (abdominal) pain

  • diarrhea

  • decreased white blood cell counts, platelet counts, and red blood cell counts

  • decreased blood calcium corrected levels

  • increased blood pancreas enzyme (lipase and amylase) levels

  • increased blood fat (cholesterol and triglycerides) levels

  • increased blood uric acid levels

  • increased blood liver enzyme levels

  • increased blood alkaline phosphatase levels

  • increased blood creatine kinase levels

Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.

SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.

Review the serious and most common side effects of SCEMBLIX here.

Everyone responds differently to treatment. That’s why it’s important to discuss the potential side effects of each treatment you and your doctor are considering to treat Ph+ CML in chronic phase.

Question mark icon

Ask your doctor about SCEMBLIX
 

Before you start on treatment for Ph+ CML in chronic phase, ask your doctor about the potential benefits and risks of different medications.

Questions to ask your doctor about SCEMBLIX as your first medication for Ph+ CML in chronic phase: 

  1. How is SCEMBLIX different from other medications that treat Ph+ CML-CP? 

  2. When might I expect to see results with SCEMBLIX?

  3. What are the most serious and common side effects of SCEMBLIX?

  4. How will I know if SCEMBLIX is working?

  5. What are some treatment milestones I should know about?

  6. What are the results of my latest blood work?